# Increased Yields and Purity for Lentivirus Production: OmniaBio's Manufacturing Approach

Zahra Sheikholeslami<sup>1</sup>, Nish Patel<sup>2</sup>, Adam McLeod<sup>3</sup>, Anna Maystrenko<sup>3</sup>, Philip Beaudette<sup>2</sup>, Karina Kawka<sup>3</sup>, Azher Razvi<sup>3</sup>, Adam Huys<sup>2</sup>, Neil Blackburn<sup>1</sup>, Shivali Joshi<sup>1</sup>, Benjamin McLeod<sup>1</sup>, Krista McNally<sup>4</sup>, Albert Gacerez<sup>4</sup>, Melissa Fardy<sup>4</sup> <sup>1</sup>OmniaBio, Hamilton, ON, <sup>2</sup>CCRM, Toronto, ON, Canada, <sup>3</sup>Cytiva, MBO, MA, USA, <sup>4</sup>Chimera Bioengineering, South San Francisco, CA, USA.

#### Introduction

- OmniaBio offers substantial expertise in process development and GMP manufacturing of potent lentiviral vectors (LVV).
- We offer two suspension serum-free HEK293 cell lines—available in cGMP and research grade that yield high LVV production

#### Transient transfection cell line

· Stable inducible packaging cell line

 Here, we showcase how our refined platform has been further optimized using:

- Design of Experiment (DoE) approaches in Upstream development
- Collaborations with Cytiva and CCRM to substantially increase product purity



## Results

## **Optimizing CAR Construct** – 2X Increase

- A series of three iterative transfection experiments were conducted at small-scale (6-well plates or 125 mL shake flasks (SF)) to optimize the expression of CAR-LVV.
- A 2X increase in titer was observed.
- The top performing condition identified in the DoE was confirmed in stirred-tank bioreactors (STR) with no loss in titer, resulting in a robust/reproduceable process.



- Upscaled the optimized process into the 3 L BioFlo<sup>™</sup> and Cytiva's Xcellerex<sup>™</sup> XDR50 single-use bioreactor and determined the culture parameter set points.
- Two proof-of-concept runs conducted, with each run involving an XDR-50 and a 3 L BioFlo<sup>™</sup> setup running in parallel.
- The final step of cell scale-up (n-1) was carried out using the XDR-50 system.
- Titers obtained from both XDR-50 runs exhibited remarkable similarity,
- No significant difference observed between the BioFlo<sup>™</sup> runs and the XDR-50 runs.

### DSP Unit Operations Performance - High recovery and GFP/CAR Equivalence

· Established a fast, scalable, and robust downstream protocol for LVV .:

- Benzonase treatment: degraded the majority of DNA below 200 bp, to meet the regulatory requirement of no open reading frames (ORF).
- Clarification: identified scalable and compatible consumables and fine-tuned this step to maximize virus recovery.
- 3) UF/DF: achieved good recovery and clearance of both protein and DNA from host cells.
- 4) Chromatography: Identified high-throughput technology and a suitable scale-down model for process development; developed a multimodal chromatography (MMC) step that combines size exclusion and anion exchange properties.
- Final sterile filtration at 0.22 μm: achieved maximized recovery by optimizing filter material, layers, and other factors.
- Notably, while this step has been known to reduce vector infectivity, Recovery>80% were observed in our process.
- The overall infectious vector recoveries of ~30% was confirmed for two CAR constructs as well (Fig 4).









Run 2

Run 3

Fig 3: Robust Scalability Confirmed in Two Proof-of-Concept Runs





## Conclusions Upstream Process

 We've finely tuned CAR construct transfection parameters, achieving not only high titer but also scalability, making it easily adaptable for client-specific processes. Downstream Process

 We've achieved an impressive 20-30% overall recovery rate while maintaining high purity, scalability, and customization for client-specific needs.









SCAN MEEE

